Scaling for Growth: Building a Foundation for Your Company’s Next Inflexion Point
By

My career as a finance executive in both biotech and medtech Life Sciences companies has included many assignments where growth was imperative, despite prevailing countercurrents in the market and the challenges this imposed internally: At Lipid Sciences, a privately held biotechnology company pursuing HDL therapies for cardiac and viral applications,…Read More

Read More
2024 Trends & FLG Partners Celebrates 20 Years of Success
By

In 2024, FLG Partners will celebrate our 20th Anniversary in business, thanks to the hundreds of clients, referral partners and industry colleagues who have helped us meet our objectives. Because of partnering with these colleagues, we have been able to close: 350+ M&A transactions 200+ IPOs 100+ Divestiture transactions And…Read More

Read More
Raising Capital in Life Sciences in 2022-2023: What Works?
By

Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More

Read More
5 Lessons in Cash Management from a CFO
By

When I joined FLG in 2020, I brought 20+ years of experience as a finance executive and CFO to the firm. My current focus is technology businesses, including B2B Software and Consumer platforms as well as Healthcare and Life Sciences. I help teams drive strategies as they plan for growth,…Read More

Read More